Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Colorectal cancer updates at ASCO 2022

Mark Yarchoan • 5 Jun 2022
ASCO 2022
Colorectal Cancer Gastrointestinal Cancer

Mark Yarchoan, MD, Johns Hopkins Medicine, Baltimore, MD, reflects on key updates presented at this year’s American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, including the use of neoadjuvant immunotherapy in mismatch repair deficient colorectal cancer, as well as the continuing investigation of circulating tumor DNA (ctDNA). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Mark Yarchoan

0:54
Exploring durvalumab + bevacizumab + TACE in hepatocellular carcinoma: EMERALD-1 insights
Mark Yarchoan • 19 Jan 2024
0:57
The evolving landscape of first-line therapies in advanced HCC
Mark Yarchoan • 19 Jan 2024
0:53
Emerging immunotherapy biomarkers for predicting systemic therapy in HCC
Mark Yarchoan • 19 Jan 2024
0:53
The mechanism of action of TPST-1120, a PPARα inhibitor
Mark Yarchoan • 6 Jun 2022

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals